RxDoctor Payments Data

Randall Brauchle, MD

Otolaryngology · Houston, TXNPI 1124005350

Payments from drug & device makers

$4,614in general payments, 2019–2025

Across 82 payments — averaging $56.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acclarent, Inc$793
  • Medtronic$669
  • Stryker$511
  • Integra Lifesciences Corporation$372
  • Optinose US, Inc.$359
  • Sanofi$300
  • plus $2K from 16 others

What the payments were for

  • Travel & lodging$90%
  • Food & beverage$4,605100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,614 in reported general payments places this provider in the 70th percentile of 729 otolaryngology providers in Texas.

See all otolaryngology providers in Texas

Medicare billing

Part B allowed, 2024
$178,460
Medicare patients
590
Services billed
5,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Epinephrine29$4,065
Ipratropium Bromide120$3,423
Azelastine Hcl116$3,152
Levocetirizine Dihydrochloride70$1,898
CefuroximeCefuroxime Axetil90$1,464
Olopatadine Hcl12$929
Ofloxacin44$830
Mupirocin60$662
Doxycycline Monohydrate21$295
Albuterol Sulfate HfaAlbuterol Sulfate15$278
Levofloxacin44$246
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$238
Montelukast Sodium31$232
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$177
Prednisone44$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$17$4,06529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 729 otolaryngology providers in Texas.

Other otolaryngology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →